Vivek Ramaswamy was born on the 9th August 1985, in Cincinnati, Ohio USA, and is an entrepreneur focused on biotechnology. He is most noted for being the founder and CEO of Roivant Sciences, Ltd. – a biopharmaceutical company focused on producing new medicines at reduced costs, and potentially improving the lives of late stage drug-dependent dementia sufferers.
Have you ever wondered how much wealth this biotech prodigy has accumulated so far? How rich Vivek Ramaswamy is? According to sources, it is estimated that the total amount of Vivek Ramaswamy’s net worth, as of early 2017, exceeds $600 million, acquired through his career in bioengineering as well as through his corporations, which have a current market worth estimated at over $3 billion.
Vivek Ramaswamy Net Worth $600 million
Vivek was born the eldest child of Gretha, a geriatric psychiatrist and V. G. Ramaswamy who was a General Electrics employee. While attending high school, Vivek was a prominent junior tennis player. Later he enrolled at the prestigious Harvard College from which he graduated summa cum laude with Bachelor of Arts degree in biology.
Subsequently, Ramaswamy continued his education and obtained his Doctor of Jurisprudence title from Yale Law School. Vivek began his professional career as a hedge fund partner and investor in the biotech sector, before in 2007 co-founding Campus Venture Network in which he also served as president before it was acquired by the Ewing Marion Kauffman Foundation in 2009. Between 2007 and 2014, Ramaswamy worked as a partner and the manager at the QVT Financial. These engagements provided the basis for Vivek Ramaswamy’s net worth.
In May 2014, Vivek Ramaswamy entirely focused on biotechnology development, and founded his own biopharmaceutical company – Roivant Sciences, Ltd. The company is focused, apart from those already mentioned above, on developing new as well as on reviving old or forgotten cures and drug formulas. It is in tight cooperation with several leading pharmaceutical companies and education institutions, such as Eisai Co., Vertex Pharmaceuticals and GlaxoSmithKline, as well as Cincinnati Children’s Hospital and Duke University. Roivant is composed of five subsidiary companies focused on several different medical sectors, including Axovan Sciences and Myovant Sciences as the biggest two. In both of these, Vivek Ramaswamy serves as a member of the Board of directors. It is certain that all these achievements have helped Ramaswamy to dramatically increase his wealth.
Besides these mentioned above, Ramaswamy is currently serving as the Arbutus Biopharma Corporation’s Board of Directors’ Chairmen, leading the company towards developing a cure for chronic hepatitis B patients. The smart combination of stock exchange market trading, developing new and buying and reviving old(er) drugs and disease cures, has helped Vivek Ramaswamy to build a pharmaceutical empire and gather an impressive amount of revenue in slightly over a three year period.
When it comes to his personal life, there are very few details of Vivek’s private life, other than that he currently resides in Manhattan, New York with his wife.
